September 23rd, 2020 | 09:05 CEST
BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?
When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.
time to read: 2 minutes
|
Author:
Mario Hose
ISIN:
US09075V1026 , NL0015436031 , CA91915B1085
Table of contents:
"[...] We believe that these findings could be of great benefit in protecting at-risk patients. [...]" David Elsley, CEO, Cardiol Therapeutics
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Tax money accelerates development
The development of medical agents is costly and time-consuming. Politicians and companies are working closely together on research into a vaccine against Covid-19. Social peace is already at stake in many countries, and for this reason, specialized companies must be given financial leeway to get to the goal as quickly as possible: the vaccine. The two German companies BioNTech and CureVac have each received pledges of taxpayers' money in the high three-digit million range with the achievement of milestones.
Strengthening the industry
BioNTech and CureVac offer investors who want to participate in the race for a vaccine with the solid legal and regulatory framework of the European Union and other developed markets. However, it should be noted that the market capitalization is already in the multi-billion range so high expectations have already been priced in. The fight against Covid-19 has brought these companies to the forefront of global competition, which is expected to strengthen the industry for the time after the pandemic, and the experience gained will also be used in other areas of the companies for the development of other products.
Access to patients generates revenue
Anyone afraid of the research and development risk should take a look at Valeo Pharma, as the company focuses on bringing to market products already tried and tested by other biotech companies. The main market for its medical products is Canada. According to its statements, Valeo Pharma can accompany the entire process of handling products. Especially for small researching market participants, specialized companies like Valeo Pharma offer an excellent sales channel. The sales staff are in direct contact with doctors and medical institutions. This is how specific prescription products find their way to the patient.
Marketing authorization enables sales offensive
In the context of the current corona pandemic, Valeo Pharma is working with its partner Ingenew. Ingenew's Hesperco capsules are designed to support the immune system and Valeo Pharma has accompanied the marketing authorization process and is now taking care of the distribution. Pierre Laurin, CEO of Ingenew, explained the importance of the active ingredient in a press release: "(...) Thousands of compounds have been evaluated since the start of the pandemic and the active compound in Hesperco capsules has been repeatedly reported to be one of the best candidate to interfere with the mechanisms SARS-CoV-2 uses to infect our cells. (…)“
Portfolio offers growth potential
Besides Hesperco, Valeo Pharma has eight other products in its portfolio and six more in the pipeline. The latest financing round provides the company with sufficient capital for a sales offensive. The company was able to raise CAD 6.9 million from investors at a share price of CAD 1.20, thus laying the foundation for the future. "(...) The proceeds of this financing will be used to support the launch of several new products in the coming months and to accelerate new growth opportunities," said Steve Saviuk, CEO of Valeo Pharma. With a market capitalization of CAD 75 million, Valeo Pharma costs only a fraction of the market capitalization of BioNTech and CureVac.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
